



G-Protein-Coupled Receptors (GPCRs)

Guest Editor:

Prof. Ujendra Kumar

Department of Pharmacology
and Toxicology, The University of
British Columbia, Vancouver, BC, Canada

Deadline for manuscript
submissions:

closed (31 May 2022)

Message from the Guest Editor

G-protein-coupled receptors (GPCRs) are the cell surface protein that constitute the largest family in the human genome (>800gene), and are involved in a wide variety of function in the peripheral and central system. GPCRs have the ability to bind or are activated by multiple ligands, including hormones, photons, ions, neurotransmitters, odorants, peptides, and light, and are involved in the regulation of multiple signaling pathways. The majority of transduction events in cells are under the influence of GPCRs, which is a testament to their significance as a major target of therapeutic drug discovery. Despite recent progress in the field of GPCRs, the structure biology of these surface proteins is poorly understood; however, functional interactions between different GPCRs, including adrenergic, cannabinoid, GABA, dopamine, opioid, and somatostatin receptor subtypes are now well established. As Guest Editor, I invite submission of manuscripts dealing with different aspects of GPCRs for publication in this Special Issue of Biomedicine.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)